Bristol Myers executive discusses safety hurdles for autoimmune CAR-T
Bristol Myers Squibb is addressing safety concerns in its CAR-T program for autoimmune diseases. In a Q&A, Lynelle Hoch discusses the challenges, and the company says it has identified the cause of a safety signal seen in a lupus trial.
Bristol Myers Squibb is working through safety questions in its effort to apply CAR-T therapy to autoimmune diseases. The company’s Lynelle Hoch addressed those challenges in a Q&A, and Bristol Myers says it has determined what caused a safety issue observed in a lupus trial. The disclosure places the program within the broader drug-development task of balancing new treatment approaches against the need to understand and manage risks. Because the available material does not detail the nature of the issue or the company’s next steps, the key takeaway is that safety review remains central to advancing this autoimmune CAR-T work.
If the company’s explanation holds, patients with autoimmune conditions such as lupus could eventually have another treatment option to discuss with clinicians, though safety data would need to be clear. Researchers and regulators may focus on how the cause was identified and whether similar risks appear in other trials. For patients and families, the story may be less about a near-term therapy than about the slower, uncertain process of turning a scientific approach into a reliably safe treatment.